GSK's Shingles Vaccine Steps Closer To Catching Zostavax
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is preparing for major filings next year for its challenger to Sanofi Pasteur MSD's Zostavax shingles vaccine, now named Shingrix (HZ/su vaccine), after promising top-line data in a second Phase III trial confirmed its benefits in an older patient population.
You may also be interested in...
Merck & Co's New Shingles Vaccine Clears First Phase III Hurdle
Merck & Co has positive data from the first of two Phase III trials of its new varicella zoster virus vaccine for the prevention of shingles in immunocompromised patients, but will the product be enough to prop up its waning Zostavax in the face of GSK's Shingrix?
GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax
The strength of more detailed data on GSK’s shingles vaccine in older people from the Phase III ZOE-70 study raises prospects Shingrix can advance into a market that Merck’s Zostavax currently has to itself.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.